Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 193

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 193
---
 amount (or approximately
$35,100 plus VAT). If a registration statement for an initial public offering is made effective no later than March 31, 2025, then
the maturity date will be extended to June 30, 2025. In addition, pursuant to the December 2024 Loan Agreement, upon the
consummation of this offering the Company will issue warrants, or the CEO Loan Warrants, exercisable for a period of three years
from the date of the issuance, to purchase such number of Ordinary Shares equal to two times the respective loan amount divided by
75% of the lowest price per Ordinary Share during the first five trading days following the consummation of this offering, at an
exercise price equal to 75% of the lowest price per Ordinary Share during the first five trading days following the consummation of
this offering. The outstanding debt will become immediately due and payable upon an event of default (as defined in the December
2024 Loan Agreement), which shall be deemed to have occurred upon certain circumstances as detailed in the December 2024 Loan
Agreement. On March 31, 2025, we and our Chief Executive Officer entered an amendment to the December 2024 Loan Agreement to extend
the maturity date until the earlier of August 31, 2025, or the consummation of an IPO. On July 1, 2025, we entered into an amendment
to the December 2024 Loan Agreement such that our Chief Executive Officer shall be granted warrants to purchase up to 55,224
Ordinary Shares following the consummation of this offering. During September 2025, the December 2024 Loan Agreement has been
extended until November 30, 2025.

In April 2025, we
entered into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained bridge loans in the aggregate amount
of $200,000 from certain lenders, including Dr. Ehud Geller, the chairman and a member of the board of directors, and Pini Ben
Elazar, a director nominee. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8% per annum until maturity.
Pursuant to the terms of the 2025 Loan Agreements, we also agreed to pay the lenders an additional risk premium equal to 50% of
their respective loan amount. The loans under the 2025 Loan Agreements mature upon the earlier